
Daina Graybosch
Stock Analyst at Leerink Partners
(0.13)
# 4,849
Out of 5,189 analysts
507
Total ratings
38.3%
Success rate
-7.9%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPHA Innate Pharma | Downgraded: Hold | $4 → $1 | $0.8634 | +15.82% | 34 | Nov 19, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Hold | $11 | $9.95 | +10.55% | 8 | Nov 19, 2026 | |
| GILD Gilead Sciences | Reiterated: Hold | $129 → $145 | $166.43 | -12.88% | 31 | Nov 2, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $161 → $162 | $133.72 | +21.15% | 80 | Nov 2, 2026 | |
| REPL Replimune Group | Reiterated: Buy | $17 → $31 | $19.07 | +62.56% | 3 | Oct 29, 2026 | |
| CRBU Caribou Biosciences | Downgraded: Hold | $1 | $0.2843 | +251.74% | 1 | Oct 7, 2026 | |
| CGEN Compugen | Reiterated: Buy | $13 → $5 | $1.84 | +171.74% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $49 → $47 | $15.62 | +200.90% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $80.96 | +39.58% | 67 | Feb 2, 2026 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $1.17 | n/a | 26 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $0.83 | n/a | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $6 | $4.91 | n/a | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $7 | $0.919 | n/a | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.9466 | n/a | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $7.56 | n/a | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.76 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.14 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.0001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $2.53 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $72.40 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $30.20 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.11 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.00001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $2.96 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 35.00 | CHF 2.05 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €86.64 → €91.20 | €146.45 | n/a | 3 | Aug 25, 2020 |
Innate Pharma
Nov 19, 2026
Downgraded: Hold
Price Target: $4 → $1
Current: $0.8634
Upside: +15.82%
Summit Therapeutics
Nov 19, 2026
Reiterated: Hold
Price Target: $11
Current: $9.95
Upside: +10.55%
Gilead Sciences
Nov 2, 2026
Reiterated: Hold
Price Target: $129 → $145
Current: $166.43
Upside: -12.88%
Merck & Co.
Nov 2, 2026
Reiterated: Buy
Price Target: $161 → $162
Current: $133.72
Upside: +21.15%
Replimune Group
Oct 29, 2026
Reiterated: Buy
Price Target: $17 → $31
Current: $19.07
Upside: +62.56%
Caribou Biosciences
Oct 7, 2026
Downgraded: Hold
Price Target: $1
Current: $0.2843
Upside: +251.74%
Compugen
May 21, 2026
Reiterated: Buy
Price Target: $13 → $5
Current: $1.84
Upside: +171.74%
Arcus Biosciences
Apr 20, 2026
Reiterated: Buy
Price Target: $49 → $47
Current: $15.62
Upside: +200.90%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $80.96
Upside: +39.58%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $1.17
Upside: n/a
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $0.83
Upside: n/a
Sep 4, 2025
Reiterated: Hold
Price Target: $20 → $6
Current: $4.91
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $7
Current: $0.919
Upside: n/a
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.9466
Upside: n/a
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $7.56
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $1.76
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $8
Current: $1.14
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.0001
Upside: n/a
Aug 28, 2024
Reiterated: Hold
Price Target: $6
Current: $2.53
Upside: n/a
Dec 11, 2023
Reiterated: Buy
Price Target: n/a
Current: $72.40
Upside: n/a
Sep 15, 2023
Reiterated: Hold
Price Target: $1.5
Current: $30.20
Upside: n/a
Jun 5, 2023
Reiterated: Buy
Price Target: n/a
Current: $2.11
Upside: n/a
Apr 27, 2022
Reiterated: Buy
Price Target: $5
Current: $0.00001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $2.96
Upside: n/a
Apr 6, 2021
Reiterated: Buy
Price Target: CHF 35.00
Current: CHF 2.05
Upside: n/a
Aug 25, 2020
Reiterated: Buy
Price Target: €86.64 → €91.20
Current: €146.45
Upside: n/a